<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>modification_summary_a_035.html</title>
</head>
<body>
<p>* The extensive discussion of prior-year financial restatements has been removed.</p>
<p>* A forward-looking outlook section with financial guidance was introduced.</p>
<p>* A new section was added to highlight operational achievements.</p>
<p>* The company announced multiple new product launches across its fixation businesses.</p>
<p>* A new company-wide process and systems improvement initiative was announced.</p>
<p>* Disclosed new research and development collaborations with clinical organizations.</p>
<p>* Revenue recognition for stimulation products now requires obtaining all payor documents.</p>
<p>* Inventory allowance is now explicitly identified as a critical accounting estimate.</p>
<p>* The company&#x27;s mission statement and general business description were revised.</p>
<p>* The corporate headquarters location is now specifically identified.</p>
<p>* A new section summarizing key annual financial highlights was added.</p>
<p>* A new accounting policy for share-based compensation was disclosed.</p>
<p>* The CEO is now identified as the chief operating decision maker.</p>
<p>* Corporate costs are redefined to explicitly include share-based compensation expenses.</p>
<p>* The BioStim product description adds emphasis on strong clinical trial support.</p>
<p>* BioStim sales growth is newly attributed to sales organization enhancements.</p>
<p>* Biologics sales growth is now attributed to an expanded sales channel.</p>
<p>* A sales channel disruption in Brazil is disclosed as a new business challenge.</p>
<p>* A sales force reorganization is cited for the decline in Spine Fixation sales.</p>
<p>* Lower sales and marketing costs are now linked to sales force reorganization efforts.</p>
<p>* G&amp;A expense increased due to new investments in internal audit and Bluecore.</p>
<p>* Increased fees on the unused revolver are a new factor in interest expense.</p>
<p>* Changes in valuation allowance and tax reserves now impact the effective tax rate.</p>
<p>* Changes in the valuation allowance were added as a factor affecting taxes.</p>
<p>* An insurance award reimbursement was noted as being offset by legal costs.</p>
<p>* A multi-year infrastructure improvement initiative named &quot;Bluecore&quot; was launched.</p>
<p>* An exclusive option agreement was entered into to acquire eNeura, Inc.</p>
<p>* The revolving credit facility&#x27;s available capacity was reduced to $100 million.</p>
<p>* A new risk regarding the upcoming expiration of the credit facility was disclosed.</p>
<p>* The total cost of the multi-year financial restatements was quantified.</p>
<p>* A new policy to indefinitely reinvest unremitted foreign earnings was disclosed.</p>
<p>* Inventory purchase commitments were newly added to contractual obligations.</p>
</body>
</html>
